SUBSCRIBE TO OUR FREE NEWSLETTER
Daily news & progressive opinion—funded by the people, not the corporations—delivered straight to your inbox.
5
#000000
#FFFFFF
5
#000000
#FFFFFF
Rep. Pramila Jayapal (D-Wash.) speaks during an oversight hearing in the Rayburn House Office Building on Capitol Hill February 8, 2019 in Washington, D.C. (Photo: Chip Somodevilla/Getty Images)
'Greed Is a Danger to Public Health': Progressive Caucus Urges Ban on Big Pharma Coronavirus Price-Gouging
"As we've seen all too often from Big Pharma, saving lives is incidental to their business model—the profit motive always comes first."
Jul 03, 2020
In the wake of Gilead's announcement that it will charge U.S. hospitals $3,120 per privately insured patient for a treatment course of Covid-19 drug remdesivir, the Congressional Progressive Caucus is calling on Congress to pass legislation combating the pharmaceutical industry's effort to "profiteer off a pandemic" by imposing exorbitant prices.
"This doesn't come as a surprise--after all, this is the same company that once priced a lifesaving Hepatitis C drug, Sovaldi, at $1000 per pill, totaling $84,000 for a single course of treatment," Reps. Pramila Jayapal (D-Wash.) and Mark Pocan (D-Wis.) said of Gilead in a statement Wednesday. "Sadly, as we've seen all too often from Big Pharma, saving lives is incidental to their business model--the profit motive always comes first."
"Big Pharma's greed is a danger to public health--Congress cannot allow it to go unaddressed any longer."
--Reps. Pramila Jayapal and Mark Pocan
Jayapal and Pocan urged the House Democratic leadership to hold a floor vote on Rep. Jan Schakowsky's (D-Ill.) Make Medications Affordable by Preventing Pandemic Price-Gouging Act, which would require the federal government to "mandate reasonable, affordable pricing of any new, taxpayer-funded Covid-19 drug used to diagnose, mitigate, prevent, or treat Covid-19."
"In a time of unprecedented national suffering, with more than 125,000 of our neighbors, coworkers, and loved ones dead from the coronavirus, Gilead has chosen to exploit the desperation of millions and profiteer off a pandemic," said Jayapal and Pocan. "But just because Gilead will exploit this pandemic, that doesn't mean that Congress should let them."
"Researchers have estimated that Gilead could cover the price of manufacturing remdesivir at scale with reasonable profit at a market price of $1 per day. But instead, Gilead plans to charge $520 a vial--an outrageous and unjustifiable mark-up," the lawmakers added. "Big Pharma's greed is a danger to public health--Congress cannot allow it to go unaddressed any longer."
The Progressive Caucus' demand comes as the Trump administration, as Common Dreams reported Thursday, actively opens the door to pharma price-gouging by refusing to exercise federal authority to hold down prices for coronavirus treatments developed with taxpayer money.
In several government contracts with pharmaceutical giants obtained by consumer advocacy group Knowledge Ecology International (KEI), the Trump administration left out a standard condition requiring that products developed with the help of federal funds be made available to the public "on reasonable terms."
"This means that the government has limited its ability to intervene if the pharmaceutical companies (which are party to the agreements and are receiving hundreds of millions of dollars to conduct the research) charge unreasonable prices for the resulting Covid-19 vaccines or treatments," said KEI.
We are at a crossroads
This country and this world are at a monumental crossroads. US voters have an opportunity to beat back the forces of fascism and confront the billionaires who are rigging the economy, our media system, and our democracy, making it increasingly impossible for ordinary people to get by. We’re not just talking about the election. We’re talking about what must be done once these fascist elements are vanquished from power. We need a bolder set of solutions than what either major party has so far been willing to offer and a working-class movement ready to fight like hell for it. Trump didn't emerge from nowhere. The conditions that fueled MAGA authoritarianism were created by decades of radical neoliberal economic policies and a corrupt political system dominated by corporate interests. They slashed taxes on the super-rich, promising that the benefits would trickle down. They said giveaways to the corporate titans would make life more affordable for the rest of us. It was all bullshit. And when a bitter, betrayed populace searches for someone to blame, right-wing demagogues have little trouble finding scapegoats. People know when they're being lied to, but you won't hear any of this from the corporate media. Only independent journalism—powered and funded by people who believe in building a better world—can deliver truly trustworthy daily news. If you share our vision, please contribute whatever you can to sustain our work. |
Our work is licensed under Creative Commons (CC BY-NC-ND 3.0). Feel free to republish and share widely.
In the wake of Gilead's announcement that it will charge U.S. hospitals $3,120 per privately insured patient for a treatment course of Covid-19 drug remdesivir, the Congressional Progressive Caucus is calling on Congress to pass legislation combating the pharmaceutical industry's effort to "profiteer off a pandemic" by imposing exorbitant prices.
"This doesn't come as a surprise--after all, this is the same company that once priced a lifesaving Hepatitis C drug, Sovaldi, at $1000 per pill, totaling $84,000 for a single course of treatment," Reps. Pramila Jayapal (D-Wash.) and Mark Pocan (D-Wis.) said of Gilead in a statement Wednesday. "Sadly, as we've seen all too often from Big Pharma, saving lives is incidental to their business model--the profit motive always comes first."
"Big Pharma's greed is a danger to public health--Congress cannot allow it to go unaddressed any longer."
--Reps. Pramila Jayapal and Mark Pocan
Jayapal and Pocan urged the House Democratic leadership to hold a floor vote on Rep. Jan Schakowsky's (D-Ill.) Make Medications Affordable by Preventing Pandemic Price-Gouging Act, which would require the federal government to "mandate reasonable, affordable pricing of any new, taxpayer-funded Covid-19 drug used to diagnose, mitigate, prevent, or treat Covid-19."
"In a time of unprecedented national suffering, with more than 125,000 of our neighbors, coworkers, and loved ones dead from the coronavirus, Gilead has chosen to exploit the desperation of millions and profiteer off a pandemic," said Jayapal and Pocan. "But just because Gilead will exploit this pandemic, that doesn't mean that Congress should let them."
"Researchers have estimated that Gilead could cover the price of manufacturing remdesivir at scale with reasonable profit at a market price of $1 per day. But instead, Gilead plans to charge $520 a vial--an outrageous and unjustifiable mark-up," the lawmakers added. "Big Pharma's greed is a danger to public health--Congress cannot allow it to go unaddressed any longer."
The Progressive Caucus' demand comes as the Trump administration, as Common Dreams reported Thursday, actively opens the door to pharma price-gouging by refusing to exercise federal authority to hold down prices for coronavirus treatments developed with taxpayer money.
In several government contracts with pharmaceutical giants obtained by consumer advocacy group Knowledge Ecology International (KEI), the Trump administration left out a standard condition requiring that products developed with the help of federal funds be made available to the public "on reasonable terms."
"This means that the government has limited its ability to intervene if the pharmaceutical companies (which are party to the agreements and are receiving hundreds of millions of dollars to conduct the research) charge unreasonable prices for the resulting Covid-19 vaccines or treatments," said KEI.
In the wake of Gilead's announcement that it will charge U.S. hospitals $3,120 per privately insured patient for a treatment course of Covid-19 drug remdesivir, the Congressional Progressive Caucus is calling on Congress to pass legislation combating the pharmaceutical industry's effort to "profiteer off a pandemic" by imposing exorbitant prices.
"This doesn't come as a surprise--after all, this is the same company that once priced a lifesaving Hepatitis C drug, Sovaldi, at $1000 per pill, totaling $84,000 for a single course of treatment," Reps. Pramila Jayapal (D-Wash.) and Mark Pocan (D-Wis.) said of Gilead in a statement Wednesday. "Sadly, as we've seen all too often from Big Pharma, saving lives is incidental to their business model--the profit motive always comes first."
"Big Pharma's greed is a danger to public health--Congress cannot allow it to go unaddressed any longer."
--Reps. Pramila Jayapal and Mark Pocan
Jayapal and Pocan urged the House Democratic leadership to hold a floor vote on Rep. Jan Schakowsky's (D-Ill.) Make Medications Affordable by Preventing Pandemic Price-Gouging Act, which would require the federal government to "mandate reasonable, affordable pricing of any new, taxpayer-funded Covid-19 drug used to diagnose, mitigate, prevent, or treat Covid-19."
"In a time of unprecedented national suffering, with more than 125,000 of our neighbors, coworkers, and loved ones dead from the coronavirus, Gilead has chosen to exploit the desperation of millions and profiteer off a pandemic," said Jayapal and Pocan. "But just because Gilead will exploit this pandemic, that doesn't mean that Congress should let them."
"Researchers have estimated that Gilead could cover the price of manufacturing remdesivir at scale with reasonable profit at a market price of $1 per day. But instead, Gilead plans to charge $520 a vial--an outrageous and unjustifiable mark-up," the lawmakers added. "Big Pharma's greed is a danger to public health--Congress cannot allow it to go unaddressed any longer."
The Progressive Caucus' demand comes as the Trump administration, as Common Dreams reported Thursday, actively opens the door to pharma price-gouging by refusing to exercise federal authority to hold down prices for coronavirus treatments developed with taxpayer money.
In several government contracts with pharmaceutical giants obtained by consumer advocacy group Knowledge Ecology International (KEI), the Trump administration left out a standard condition requiring that products developed with the help of federal funds be made available to the public "on reasonable terms."
"This means that the government has limited its ability to intervene if the pharmaceutical companies (which are party to the agreements and are receiving hundreds of millions of dollars to conduct the research) charge unreasonable prices for the resulting Covid-19 vaccines or treatments," said KEI.
We've had enough. The 1% own and operate the corporate media. They are doing everything they can to defend the status quo, squash dissent and protect the wealthy and the powerful. The Common Dreams media model is different. We cover the news that matters to the 99%. Our mission? To inform. To inspire. To ignite change for the common good. How? Nonprofit. Independent. Reader-supported. Free to read. Free to republish. Free to share. With no advertising. No paywalls. No selling of your data. Thousands of small donations fund our newsroom and allow us to continue publishing. Can you chip in? We can't do it without you. Thank you.
To inform. To inspire. To ignite change for the common good.
News & Opinion
Trending
Common Dreams, Inc. Founded 1997. Registered 501(c3) Non-Profit
Privacy Policy